Overview Treatment of HFpEF With Nitrate Supplement Status: Completed Trial end date: 2018-08-22 Target enrollment: Participant gender: Summary The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients. Phase: Early Phase 1 Details Lead Sponsor: MaineHealthPenobscot Bay Medical CenterCollaborator: HumanN